TY - JOUR
T1 - Pharmacogenomic overlap between antidepressant treatment response in major depression & antidepressant associated treatment emergent mania in bipolar disorder
AU - Nuñez, Nicolas A.
AU - Coombes, Brandon J.
AU - Beaupre, Lindsay Melhuish
AU - Ozerdem, Aysegul
AU - Resendez, Manuel Gardea
AU - Romo-Nava, Francisco
AU - Bond, David J.
AU - Veldic, Marin
AU - Singh, Balwinder
AU - Moore, Katherine M.
AU - Betcher, Hannah K.
AU - Kung, Simon
AU - Prieto, Miguel L.
AU - Fuentes, Manuel
AU - Ercis, Mete
AU - Miola, Alessandro
AU - Sanchez Ruiz, Jorge A.
AU - Jenkins, Gregory
AU - Batzler, Anthony
AU - Leung, Jonathan G.
AU - Cuellar-Barboza, Alfredo
AU - Tye, Susannah J.
AU - McElroy, Susan L.
AU - Biernacka, Joanna M.
AU - Frye, Mark A.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - There is increasing interest in individualizing treatment selection for more than 25 regulatory approved treatments for major depressive disorder (MDD). Despite an inconclusive efficacy evidence base, antidepressants (ADs) are prescribed for the depressive phase of bipolar disorder (BD) with oftentimes, an inadequate treatment response and or clinical concern for mood destabilization. This study explored the relationship between antidepressant response in MDD and antidepressant-associated treatment emergent mania (TEM) in BD. We conducted a genome-wide association study (GWAS) and polygenic score analysis of TEM and tested its association in a subset of BD-type I patients treated with SSRIs or SNRIs. Our results did not identify any genome-wide significant variants although, we found that a higher polygenic score (PGS) for antidepressant response in MDD was associated with higher odds of TEM in BD. Future studies with larger transdiagnostic depressed cohorts treated with antidepressants are encouraged to identify a neurobiological mechanism associated with a spectrum of depression improvement from response to emergent mania.
AB - There is increasing interest in individualizing treatment selection for more than 25 regulatory approved treatments for major depressive disorder (MDD). Despite an inconclusive efficacy evidence base, antidepressants (ADs) are prescribed for the depressive phase of bipolar disorder (BD) with oftentimes, an inadequate treatment response and or clinical concern for mood destabilization. This study explored the relationship between antidepressant response in MDD and antidepressant-associated treatment emergent mania (TEM) in BD. We conducted a genome-wide association study (GWAS) and polygenic score analysis of TEM and tested its association in a subset of BD-type I patients treated with SSRIs or SNRIs. Our results did not identify any genome-wide significant variants although, we found that a higher polygenic score (PGS) for antidepressant response in MDD was associated with higher odds of TEM in BD. Future studies with larger transdiagnostic depressed cohorts treated with antidepressants are encouraged to identify a neurobiological mechanism associated with a spectrum of depression improvement from response to emergent mania.
UR - http://www.scopus.com/inward/record.url?scp=85185138734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85185138734&partnerID=8YFLogxK
U2 - 10.1038/s41398-024-02798-y
DO - 10.1038/s41398-024-02798-y
M3 - Article
C2 - 38351009
AN - SCOPUS:85185138734
SN - 2158-3188
VL - 14
JO - Translational psychiatry
JF - Translational psychiatry
IS - 1
M1 - 93
ER -